Aktis Oncology AKTS
NASDAQ AKTS
$16.62 +0.34 (+2.09%)
At close: Nov 13, 2026 · 4:00 PM EST

Aktis Oncology (AKTS) Return on Equity [ROE] (2026)

Updated

Aktis Oncology (AKTS) posted Return on Equity [ROE] of -18.97% for Q3 2026, down 4.06 percentage points from the prior quarter.

Analysis

Aktis Oncology (AKTS) Return on Equity [ROE] (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn 74.39%
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn 19.33%
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn -
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn 5.63%
5 Novartis Ag 306.35 Bn 279.93 Bn - -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn 21.60%
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn 72.13%
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn -31.17%
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn 4.66%
10 Aktis Oncology 895.95 Mn 335.72 Mn - -18.97%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -18.97%
Jun 30, 2026 -15.43%
API Access

Aktis Oncology Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=AKTS&period=max&api_key=YOUR_API_KEY